Candel therapeutics announces publication of phase 1b clinical trial data on the combination of can-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma patients

Data published in neuro-oncology demonstrate promising safety profile and potential survival benefit when combining can-2409 and nivolumab with standard of care data published in neuro-oncology demonstrate promising safety profile and potential survival benefit when combining can-2409 and nivolumab with standard of care
CADL Ratings Summary
CADL Quant Ranking